Drug & Market Development Productions has released a new market report entitled Commercial Opportunities in RNA Interference — The Emerging Revolution.
The report, said D&MD, includes assessments of the projected market impact of RNAi through 2008, the commercial opportunities for using related technologies, those in the industry, the patenting of RNAi, and the technical aspects of the technology.
The chapters of the report can be ordered separately for prices ranging from $250 to $1,000, and the entire report can be purchased for $4,950. Details about the report can be found at http://www.drugand market.com/9126.
Agilent said this week that it has introduced the Agilent Total, a new RNA isolation kit it claims is capable of removing 1,000 times more genomic DNA than competing products.
According to Agilent, the kit does not use DNase enzyme, which can compromise the quality of RNA, and it has a pre-filtration column that removes genomic DNA contamination to less than one femtogram per one nanogram of isolated RNA in selected tissues.
Details about the Agilent Total, which is to be made available on Nov. 1, can be found at www.agilent.com/chem/dna.